Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.

Guffanti F, Fratelli M, Ganzinelli M, Bolis M, Ricci F, Bizzaro F, Chilà R, Sina FP, Fruscio R, Lupia M, Cavallaro U, Cappelletti MR, Generali D, Giavazzi R, Damia G.

Oncotarget. 2018 May 15;9(37):24707-24717. doi: 10.18632/oncotarget.25185. eCollection 2018 May 15.


Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.

Ricci F, Guffanti F, Damia G, Broggini M.

Mol Cancer. 2017 May 30;16(1):97. doi: 10.1186/s12943-017-0662-3.


In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.

Guffanti F, Chilà R, Bello E, Zucchetti M, Zangarini M, Ceriani L, Ferrari M, Lupi M, Jacquet-Bescond A, Burbridge MF, Pierrat MJ, Damia G.

Neoplasia. 2017 Jan;19(1):35-42. doi: 10.1016/j.neo.2016.11.008. Epub 2016 Dec 15.


The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.

Rulli E, Guffanti F, Caiola E, Ganzinelli M, Damia G, Garassino MC, Piva S, Ceppi L, Broggini M, Marabese M.

Sci Rep. 2016 Dec 14;6:39217. doi: 10.1038/srep39217.


The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.

Guffanti F, Fruscio R, Rulli E, Damia G.

Sci Rep. 2016 Dec 1;6:38142. doi: 10.1038/srep38142.


Role and therapeutic potential of CDK12 in human cancers.

Chilà R, Guffanti F, Damia G.

Cancer Treat Rev. 2016 Nov;50:83-88. doi: 10.1016/j.ctrv.2016.09.003. Epub 2016 Sep 14. Review.


Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.

Ricci F, Fratelli M, Guffanti F, Porcu L, Spriano F, Dell'Anna T, Fruscio R, Damia G.

Oncotarget. 2017 Jan 31;8(5):7441-7451. doi: 10.18632/oncotarget.7465.


Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.

Pinessi D, Ostano P, Borsotti P, Bello E, Guffanti F, Bizzaro F, Frapolli R, Bani MR, Chiorino G, Taraboletti G, Resovi A.

Connect Tissue Res. 2015;56(5):355-63. doi: 10.3109/03008207.2015.1045065. Epub 2015 Jun 15.


Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.

Chilà R, Basana A, Lupi M, Guffanti F, Gaudio E, Rinaldi A, Cascione L, Restelli V, Tarantelli C, Bertoni F, Damia G, Carrassa L.

Oncotarget. 2015 Feb 20;6(5):3394-408.


Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations.

Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, Ghilardi C, Perego P, Fruscio R, Buda A, Milani R, Ostano P, Chiorino G, Bani MR, Damia G, Giavazzi R.

Cancer Res. 2014 Dec 1;74(23):6980-90. doi: 10.1158/0008-5472.CAN-14-0274. Epub 2014 Oct 10.

Supplemental Content

Loading ...
Support Center